Circulating Markers of Liver Function and Cardiovascular Disease Risk

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 11, 2015, Pages 2290-2296

  Targher, Giovanni ^a   Byrne, Christopher D ^b,c  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^c UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

bilirubin; cardiovascular diseases; gamma glutamyltransferase; transaminases

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; BIOLOGICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; HEME OXYGENASE;

AMINO ACID METABOLISM; ARTERIAL WALL THICKNESS; ARTICLE; BONE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; ETHNIC DIFFERENCE; GENE EXPRESSION; GENETIC VARIABILITY; GLUCONEOGENESIS; GLUCURONIDATION; HUMAN; LIFESTYLE MODIFICATION; LIVER FUNCTION; LIVER FUNCTION TEST; META ANALYSIS (TOPIC); NONALCOHOLIC FATTY LIVER; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; SYSTEMATIC REVIEW (TOPIC); ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; COMPLICATION; ENZYME ASSAY; ENZYMOLOGY; LIVER; LIVER DISEASES; PREDICTIVE VALUE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BIOMARKERS; CARDIOVASCULAR DISEASES; CLINICAL ENZYME TESTS; HUMANS; LIVER; LIVER DISEASES; LIVER FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84944909452     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.305235     Document Type: Article

References (62)

1. Mason JE, Starke RD, Van Kirk JE, Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol 2010 13 36 41. doi: 10.1111/j.1751-7141.2009.00054.x
2. Jiang S, Jiang D, Tao Y, Role of gamma-glutamyltransferase in cardiovascular diseases. Exp Clin Cardiol 2013 18 53 56
3. Lee DH, Blomhoff R, Jacobs DR Jr, Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic Res 2004 38 535 539
4. Wannamethee G, Ebrahim S, Shaper AG, Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995 142 699 708
5. Kunutsor SK, Apekey TA, Seddoh D, Walley J, Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol 2014 43 187 201. doi: 10.1093/ije/dyt192
6. Koehler EM, Sanna D, Hansen BE, van Rooij FJ, Heeringa J, Hofman A, Tiemeier H, Stricker BH, Schouten JN, Janssen HL, Serum liver enzymes are associated with all-cause mortality in an elderly population. Liver Int 2014 34 296 304. doi: 10.1111/liv.12311
7. Du G, Song Z, Zhang Q, Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med 2013 57 31 37. doi: 10.1016/j.ypmed.2013.03.011
8. Targher G, Elevated serum gamma-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer-a narrative review. Clin Chem Lab Med 2010 48 147 157. doi: 10.1515/CCLM.2010.031
9. Kengne AP, Czernichow S, Stamatakis E, Hamer M, Batty GD, Gamma-glutamyltransferase and risk of cardiovascular disease mortality in people with and without diabetes: pooling of three British Health Surveys. J Hepatol 2012 57 1083 1089. doi: 10.1016/j.jhep.2012.06.034
10. Du G, Song Z, Zhang Q, Gamma-glutamyltransferase is associated with cardiovascular and all-cause mortality: a meta-analysis of prospective cohort studies. Prev Med 2013 57 31 37. doi: 10.1016/j.ypmed.2013.03.011
11. Fraser A, Harris R, Sattar N, Ebrahim S, Smith GD, Lawlor DA, Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007 27 2729 2735. doi: 10.1161/ATVBAHA.107.152298
12. Ghouri N, Preiss D, Sattar N, Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data. Hepatology 2010 52 1156 1161. doi: 10.1002/hep.23789
13. Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H, Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2013 12 CD008623. doi: 10.1002/14651858.CD008623.pub2
14. Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Dullaart RP, Circulating gamma glutamyltransferase and prediction of cardiovascular disease. Atherosclerosis 2015 238 356 364. doi: 10.1016/j.atherosclerosis.2014.12.045
15. Franzini M, Ottaviano V, Fierabracci V, Bramanti E, Zyw L, Barsacchi R, Scatena F, Boni C, Mammini C, Passino C, Pompella A, Emdin M, Paolicchi A, Fractions of plasma gamma-glutamyltransferase in healthy individuals: reference values. Clin Chim Acta 2008 395 188 189. doi: 10.1016/j.cca.2008.06.005
16. Franzini M, Fornaciari I, Rong J, Larson MG, Passino C, Emdin M, Paolicchi A, Vasan RS, Correlates and reference limits of plasma gamma-glutamyltransferase fractions from the Framingham Heart Study. Clin Chim Acta 2013 417 19 25. doi: 10.1016/j.cca.2012.12.002
17. Emdin M, Pompella A, Paolicchi A, Gamma-glutamyltransferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005 112 2078 2080. doi: 10.1161/CIRCULATIONAHA.105.571919
18. Franzini M, Corti A, Martinelli B, Del Corso A, Emdin M, Parenti GF, Glauber M, Pompella A, Paolicchi A, Gamma-glutamyltransferase activity in human atherosclerotic plaques-biochemical similarities with the circulating enzyme. Atherosclerosis 2009 202 119 127. doi: 10.1016/j.atherosclerosis.2008.03.023
19. Lee DH, Steffes MW, Sjödin A, Jones RS, Needham LL, Jacobs DR Jr, Low dose organochlorine pesticides and polychlorinated biphenyls predict obesity, dyslipidemia, and insulin resistance among people free of diabetes. PLoS One 2011 6 e15977. doi: 10.1371/journal.pone.0015977
20. Lee DH, Gross MD, Steffes MW, Jacobs DR Jr, Is serum gamma-glutamyltransferase a biomarker of xenobiotics, which are conjugated by glutathione? Arterioscler Thromb Vasc Biol 2008 28 e26 e28. doi: 10.1161/ATVBAHA.107.159376
21. Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR, Jansen PL, Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994 269 17960 17964
22. Bigo C, Caron S, Dallaire-Théroux A, Barbier O, Nuclear receptors and endobiotics glucuronidation: the good, the bad, and the UGT. Drug Metab Rev 2013 45 34 47. doi: 10.3109/03602532.2012.751992
23. Novotný L, Vítek L, Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood) 2003 228 568 571
24. Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP, Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol 2015 35 716 724. doi: 10.1161/ATVBAHA.114.304929
25. Kim KM, Kim BT, Park SB, Cho DY, Je SH, Kim KN, Serum total bilirubin concentration is inversely correlated with Framingham risk score in Koreans. Arch Med Res 2012 43 288 293. doi: 10.1016/j.arcmed.2012.05.003
26. Lin LY, Kuo HK, Hwang JJ, Lai LP, Chiang FT, Tseng CD, Lin JL, Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents. Atherosclerosis 2009 203 563 568. doi: 10.1016/j.atherosclerosis.2008.07.021
27. Perlstein TS, Pande RL, Beckman JA, Creager MA, Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol 2008 28 166 172. doi: 10.1161/ATVBAHA.107.153262
28. Perlstein TS, Pande RL, Creager MA, Weuve J, Beckman JA, Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008 121 781 788.e1. doi: 10.1016/j.amjmed.2008.03.045
29. Kimm H, Yun JE, Jo J, Jee SH, Low serum bilirubin level as an independent predictor of stroke incidence: a prospective study in Korean men and women. Stroke 2009 40 3422 3427. doi: 10.1161/STROKEAHA.109.560649
30. Zhu C, Xiong Z, Zheng Z, Chen Y, Chen X, Qian X, Association of arterial stiffness with serum bilirubin levels in established coronary artery disease. Intern Med 2012 51 2083 2089
31. Tanaka M, Fukui M, Tomiyasu K, Akabame S, Nakano K, Hasegawa G, Oda Y, Nakamura N, Low serum bilirubin concentration is associated with coronary artery calcification (CAC). Atherosclerosis 2009 206 287 291. doi: 10.1016/j.atherosclerosis.2009.02.010
32. Zhang ZY, Bian LQ, Kim SJ, Zhou CC, Choi YH, Inverse relation of total serum bilirubin to coronary artery calcification score detected by multidetector computed tomography in males. Clin Cardiol 2012 35 301 306. doi: 10.1002/clc.21964
33. Horsfall LJ, Nazareth I, Petersen I, Cardiovascular events as a function of serum bilirubin levels in a large, statin-treated cohort. Circulation 2012 126 2556 2564. doi: 10.1161/CIRCULATIONAHA.112.114066
34. Borucki K, Weikert C, Fisher E, Jakubiczka S, Luley C, Westphal S, Dierkes J, Haplotypes in the UGT1A1 gene and their role as genetic determinants of bilirubin concentration in healthy German volunteers. Clin Biochem 2009 42 1635 1641. doi: 10.1016/j.clinbiochem.2009.08.011
35. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F, Association between the UGT1A1∗28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation 2006 114 1476 1481. doi: 10.1161/CIRCULATIONAHA.106.633206
36. Bosma PJ, van der Meer IM, Bakker CT, Hofman A, Paul-Abrahamse M, Witteman JC, UGT1A1∗28 allele and coronary heart disease: the Rotterdam Study. Clin Chem 2003 49 1180 1181
37. Rantner B, Kollerits B, Anderwald-Stadler M, Klein-Weigel P, Gruber I, Gehringer A, Haak M, Schnapka-Köpf M, Fraedrich G, Kronenberg F, Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin Chem 2008 54 851 857. doi: 10.1373/clinchem.2007.102046
38. Gajdos V, Petit FM, Perret C, Mollet-Boudjemline A, Colin P, Capel L, Nicaud V, Evans A, Arveiler D, Parisot F, Francoual J, Genin E, Cambien F, Labrune P, Further evidence that the UGT1A1∗28 allele is not associated with coronary heart disease: The ECTIM Study. Clin Chem 2006 52 2313 2314. doi: 10.1373/clinchem.2006.078667
39. Ki CS, Lee KA, Lee SY, Kim HJ, Cho SS, Park JH, Cho S, Sohn KM, Kim JW, Haplotype structure of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and its relationship to serum total bilirubin concentration in a male Korean population. Clin Chem 2003 49 2078 2081. doi: 10.1373/clinchem.2003.024174
40. Seppen J, Bosma P, Bilirubin, the gold within. Circulation 2012 126 2547 2549. doi: 10.1161/CIRCULATIONAHA.112.147082
41. Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, Guerci AD, Lima JA, Rader DJ, Rubin GD, Shaw LJ, Wiegers SE, American Heart Association Committee on Cardiovascular Imaging and Intervention; American Heart Association Council on Cardiovascular Radiology and Intervention; American Heart Association Committee on Cardiac Imaging, Council on Clinical Cardiology Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 2006 114 1761 1791. doi: 10.1161/CIRCULATIONAHA.106.178458
42. Sung KC, Shin J, Lim YH, Wild SH, Byrne CD, Relation of conjugated bilirubin concentrations to the presence of coronary artery calcium. Am J Cardiol 2013 112 1873 1879. doi: 10.1016/j.amjcard.2013.08.018
43. Kontush A, Spranger T, Reich A, Djahansouzi S, Karten B, Braesen JH, Finckh B, Kohlschütter A, Beisiegel U, Whole plasma oxidation assay as a measure of lipoprotein oxidizability. Biofactors 1997 6 99 109
44. Wu TW, Fung KP, Wu J, Yang CC, Weisel RD, Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol 1996 51 859 862
45. Ryter SW, Bile pigments in pulmonary and vascular disease. Front Pharmacol 2012 3 39. doi: 10.3389/fphar.2012.00039
46. Baranano DE, Rao M, Ferris CD, Snyder SH, Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci USA 2002 99 16093 16098. doi: 10.1073/pnas.252626999
47. Franchini M, Targher G, Lippi G, Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons? Adv Clin Chem 2010 50 47 63
48. Targher G, Risk of ischemic stroke and decreased serum bilirubin levels: is there a causal link? Arterioscler Thromb Vasc Biol 2014 34 702 704. doi: 10.1161/ATVBAHA.114.303279
49. Poupon R, Liver alkaline phosphatase: a missing link between choleresis and biliary inflammation [published online ahead of print February 24, 2015]. Hepatology. doi: 10.1002/hep.27715. http://onlinelibrary.wiley.com/doi/10.1002/hep.27715/abstract;jsessionid=C56F3965C17C16168669B2FC58FE0EE7.f02t04
50. Goessling W, Massaro JM, Vasan RS, D'Agostino RB Sr, Ellison RC, Fox CS, Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008 135 1935 44, 1944.e1. doi: 10.1053/j.gastro.2008.09.018
51. Ruhl CE, Everhart JE, Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 2009 136 477 85.e11. doi: 10.1053/j.gastro.2008.10.052
52. Olynyk JK, Knuiman MW, Divitini ML, Davis TM, Beilby J, Hung J, Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol 2009 104 1715 1722. doi: 10.1038/ajg.2009.229
53. Yun KE, Shin CY, Yoon YS, Park HS, Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009 205 533 537. doi: 10.1016/j.atherosclerosis.2008.12.012
54. Schindhelm RK, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD, Heine RJ, Diamant M, Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis 2007 191 391 396. doi: 10.1016/j.atherosclerosis.2006.04.006
55. Kunutsor SK, Apekey TA, Khan H, Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis 2014 236 7 17. doi: 10.1016/j.atherosclerosis.2014.06.006
56. Wannamethee SG, Sattar N, Papcosta O, Lennon L, Whincup PH, Alkaline phosphatase, serum phosphate, and incident cardiovascular disease and total mortality in older men. Arterioscler Thromb Vasc Biol 2013 33 1070 1076. doi: 10.1161/ATVBAHA.112.300826
57. Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML, Wiebe N, Muntner P, Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation 2009 120 1784 1792. doi: 10.1161/CIRCULATIONAHA.109.851873
58. Park JB, Kang DY, Yang HM, Cho HJ, Park KW, Lee HY, Kang HJ, Koo BK, Kim HS, Serum alkaline phosphatase is a predictor of mortality, myocardial infarction, or stent thrombosis after implantation of coronary drug-eluting stent. Eur Heart J 2013 34 920 931. doi: 10.1093/eurheartj/ehs419
59. Targher G, Day CP, Bonora E, Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010 363 1341 1350. doi: 10.1056/NEJMra0912063
60. Anstee QM, Targher G, Day CP, Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013 10 330 344. doi: 10.1038/nrgastro.2013.41
61. Byrne CD, Targher G, Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014 34 1155 1161. doi: 10.1161/ATVBAHA.114.303034
62. Marchesini G, Targher G, Commentary: Liver enzymes and the risk of adverse cardiovascular outcomes-the lower, the better? Int J Epidemiol 2011 40 1539 1541. doi: 10.1093/ije/dyr187